3M Cut Its Dividend After 64 Years of Raises. Is It Finally a Buy Again?

3M’s quarterly dividend has risen to $0.78 from $0.70 after the 2024 spinoff cut, implying a 1.67% yield; the payout is about 34% of the low end of raised 2026 adjusted EPS guidance of $9.10–$9.15. The company announced a broad resolution of AFFF personal-injury litigation and authorized $6 billion in buybacks, but PFAS payments totaled $3.5 billion in 2025 and helped drive Q3 operating cash flow down 72.32% to $486 million. Management forecasts about $4.8 billion of full-year free cash flow; investors are watching settlement-payment timing and whether the expected Q4 working-capital reversal occurs.

Analysis

The key underwriting question is not whether the reset dividend is covered by adjusted EPS; it is whether cash left after legal and environmental obligations can support dividends, buybacks, and reinvestment at the same time. Adjusted EPS coverage can look comfortable while settlement timing and working-capital swings make near-term cash generation lumpy. The announced litigation framework reduces uncertainty, but does not by itself establish the remaining cash-payment schedule or eliminate other PFAS exposure. Treat the buyback authorization as discretionary capital allocation—not evidence that the liability overhang is resolved.

Over the next quarter, the expected working-capital reversal is a test of cash-conversion quality. Over 1–3 months, settlement payment timing and updated free-cash-flow guidance matter more to payout durability than the size of the next dividend increase. Over 6–18 months, the income case depends on operating growth replacing cash consumed by legacy liabilities; data-center exposure is a possible offset, not yet a demonstrated earnings driver in the supplied information.

At roughly 20x forward earnings and a 1.67% yield, MMM offers limited income compensation for execution and liability uncertainty. The article's comparison with EMR establishes a similar stated payout share of FCF, not equivalent cash-flow risk or valuation; HON's post-separation profile also needs standalone history. Contrarian point: resumed increases may create a dividend-reliability narrative before investors have seen a full cycle of post-settlement cash conversion. The thesis improves if operating cash flow rebounds without relying on working-capital timing and the company funds obligations while maintaining the payout; it weakens on missed cash-flow guidance, a higher settlement burden, or renewed guidance cuts.

Key Decisions for Investors

• Do not buy MMM solely for income at the current yield. For existing positions, keep exposure sized as a growth-and-income holding rather than a bond substitute; reassess after the next reported cash-flow and settlement update.
• Set a near-term alert on the expected Q4 working-capital reversal and full-year FCF delivery. If cash conversion disappoints and guidance is not reaffirmed, reduce exposure; if it delivers while liability payments remain within the disclosed plan, the payout case gains credibility.
• Before treating the legal resolution as a de-risking catalyst, verify the settlement payment schedule and any remaining PFAS-related cash obligations. A framework without quantified timing is not equivalent to cash-flow certainty.
• Keep EMR as a comparison/watchlist name, not an automatic long against MMM: the supplied payout ratios alone do not establish relative value. Check comparable valuation, post-separation cash-flow history, and liability-adjusted FCF before initiating a pair.